EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Premature Atrial Contractions as a Marker of Atrial Cardiopathy: A Revised Analysis of the ARCADIA Randomized Trial

Adi Elias, Justin T Teraoka iD, Elsayed Z Soliman, Mitchell S V Elkind, Hooman Kamel, Richard A Kronmal, W T Longstreth, David L Tirschwell, Marco R Di Tullio, Gregory M Marcus

Journal of Cardiovascular Electrophysiology · 2025

DOI: 10.1111/jce.16629 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2025. Verfasst von Adi Elias und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Pyrazoles, Atrial Premature Complexes, Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, This study was supported by National Institutes of Health (Grant Number 1U01NS095869), BMS-Pfizer Alliance, and Roche Diagnostics., National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Atrial cardiopathy may be associated with an increased risk of stroke independent of atrial fibrillation (AF). In the ARCADIA trial, apixaban was not superior to aspirin in preventing recurrent stroke among patients with a cryptogenic stroke and atrial cardiopathy. We aimed to determine whether the presence of at least one premature atrial complex (PAC), a known harbinger of AF and stroke, would enhance the ability to identify individuals most likely to benefit from apixaban.

Methods

In ARCADIA, atrial cardiopathy was defined by NT‐proBNP > 250 pg/mL, a P‐wave terminal force greater than 5000 μV × ms in lead V1, or a left atrial diameter index ≥ 3 cm/m² on echocardiogram. For the current analysis, the presence of any PAC on the baseline 12‐lead ECG was substituted for the less atrial‐specific NT‐proBNP criterion. The presence of any PAC was also assessed as a sole atrial cardiopathy criterion.

Results

Of the 1015 patients randomized in ARCADIA, 85 had at least one PAC. The revised atrial cardiopathy criteria were met by 593 patients; 301 were randomized to apixaban and 292 to aspirin. The annualized recurrent stroke rates were 3.1% for apixaban versus 4.4% for aspirin (HR 0.71, 95% CI: 0.38–1.34, p = 0.29). No differences in risk of recurrent stroke among participants with PACs, compared to those without PACs, were observed.

Conclusion

In patients enrolled in the ARCARDIA trial, utilizing the presence of PACs as a potential marker of atrial cardiopathy did not reveal definitive evidence of benefit of apixaban compared to aspirin. Trial Registration: ClinicalTrials.gov identifier: NCT03192215.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesAtrial Premature ComplexesAtrial FibrillationStrokeHumansMaleFemalePyridonesAspirinAgedMiddle AgedFactor Xa InhibitorsPeptide FragmentsNatriuretic Peptide, BrainBiomarkersTreatment OutcomeRisk FactorsElectrocardiographyPredictive Value of Tests

Stichwörter der Autor:innen

apixabanatrial cardiopathycryptogenic strokepremature atrial complexes

Substanzen

apixabanPyridonesPyrazolesAspirinFactor Xa InhibitorsPeptide FragmentsNatriuretic Peptide, Brainpro-brain natriuretic peptide (1-76)Biomarkers

Autor:innen und Institutionen

  • Division of Cardiology, University of California San Francisco, San Francisco, California, USA.
  • Department of Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Neurology, Vagelos College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA.
  • Department of Neurology, Weill Cornell Medicine, New York, New York, USA.
  • Department of Biostatistics, University of Washington Seattle, Seattle, Washington, USA.
  • Department of Neurology, University of Washington, Seattle, Wishington, USA.

ORCID-Profile: Justin T Teraoka

Förderung

  • NINDS NIH HHS
  • This study was supported by National Institutes of Health (Grant Number 1U01NS095869), BMS-Pfizer Alliance, and Roche Diagnostics.
  • National Institutes of Health

Zitieren

APA

Elias, A., Teraoka, J. T., Soliman, E. Z., Elkind, M. S. V., Kamel, H., Kronmal, R. A., Longstreth, W. T., Tirschwell, D. L., Di Tullio, M. R., & Marcus, G. M. (2025). Premature Atrial Contractions as a Marker of Atrial Cardiopathy: A Revised Analysis of the ARCADIA Randomized Trial. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16629

Vancouver

Elias A, Teraoka JT, Soliman EZ, Elkind MSV, Kamel H, Kronmal RA, et al. Premature Atrial Contractions as a Marker of Atrial Cardiopathy: A Revised Analysis of the ARCADIA Randomized Trial. Journal of Cardiovascular Electrophysiology. 2025. doi:10.1111/jce.16629

BibTeX
@article{Elias2025,
  author = {Elias, Adi and Teraoka, Justin T and Soliman, Elsayed Z and Elkind, Mitchell S V and Kamel, Hooman and Kronmal, Richard A and Longstreth, W T and Tirschwell, David L and Di Tullio, Marco R and Marcus, Gregory M},
  title = {Premature Atrial Contractions as a Marker of Atrial Cardiopathy: A Revised Analysis of the ARCADIA Randomized Trial},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2025},
  doi = {10.1111/jce.16629}
}
Kostenlos starten →